Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a frontrunner in AI-driven cardiovascular medicine, has unveiled its newly redesigned website, CDIO.AI. This upgraded platform underscores the Company’s commitment to an AI-first approach and showcases its advanced, scalable solutions for preventing, detecting, and managing cardiovascular disease—the leading cause of death worldwide. The new site aims to streamline access to vital information for investors, partners, patients, providers, and other stakeholders.
The redesigned CDIO.AI site significantly enhances user experience, offering intuitive navigation for all visitor types. Investors can easily access financial reports, stock data, and corporate governance information. Patients will find straightforward details about Cardio Diagnostics’ tests and acquisition procedures, while healthcare providers benefit from simplified ordering processes and test interpretation resources. Additionally, the site includes tailored content for payers, employers, researchers, and pharmaceutical companies, highlighting the value of Cardio Diagnostics’ solutions in population health management and collaborative opportunities.
The website features three key AI-driven solutions:
- Epi+Gen CHD Test: Utilizes AI to assess three-year risk for coronary heart disease, including heart attacks, by analyzing genetic and epigenetic biomarkers.
- PrecisionCHD Test: Integrates epigenetics, genetics, and AI for detecting and managing coronary heart disease, offering a highly sensitive diagnostic tool that surpasses traditional methods.
- Actionable Clinical Intelligence (ACI) Platform: Combines test results with patient-specific data to provide actionable insights, enhancing personalized decision-making for heart disease management and prevention.
The site reinforces Cardio Diagnostics’ role as a leader in precision cardiovascular medicine through AI innovation. It better reflects the Company’s mission to revolutionize cardiovascular care with advanced diagnostics and personalized prevention strategies.
Tim Dogan, Ph.D., Chief Technology Officer, remarked, “The new CDIO.AI website demonstrates our dedication to innovation and user-centric design. It effectively showcases our AI solutions and makes our advanced technologies more accessible and understandable to all stakeholders.”
The updated site also features a resource center with educational materials, scientific publications, and solution documents. Healthcare providers can now order tests more efficiently, and investors benefit from an accessible investor relations portal with comprehensive financial information and resources.
Meesha Dogan, Ph.D., CEO and Co-Founder, added, “CDIO.AI is a testament to our identity as an AI-driven precision medicine company. We’ve reimagined our digital presence to highlight our AI solutions and provide a seamless experience for everyone interacting with our brand.”
About Cardio Diagnostics
Cardio Diagnostics is an AI-powered precision cardiovascular medicine company focused on enhancing the prevention, detection, and management of cardiovascular disease. Leveraging its proprietary AI-driven Integrated Genetic-Epigenetic Engine, the Company aims to lead the medical technology field with advanced solutions for cardiovascular health.
